valproic acid has been researched along with niacin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nezu, JI; Ohashi, R; Oku, A; Sai, Y; Shimane, M; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
| Amano, O; Izeki, S; Kido, Y; Ogihara, T; Ono, A; Sai, Y; Satoh, E; Takanaga, H; Tamai, I; Tsuji, A; Yabuuchi, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Gillman, MA; Sandyk, R | 1 |
| Higashida, H; Maeda, H; Ogihara, T; Sai, Y; Takanaga, H; Tamai, I; Tsuji, A | 1 |
| Bartels, H; Hebestreit, H; Mingers, AM; Pannenbecker, J | 1 |
1 review(s) available for valproic acid and niacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for valproic acid and niacin
| Article | Year |
|---|---|
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
Topics: Biological Transport, Active; Carnitine; Carrier Proteins; Cations; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Humans; Hydrogen-Ion Concentration; Kidney; Membrane Proteins; Organic Cation Transport Proteins; Sodium; Solute Carrier Family 22 Member 5; Stereoisomerism | 1999 |
Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1.
Topics: Amino Acid Sequence; Animals; Benzoic Acid; Biological Transport; Carboxylic Acids; Carrier Proteins; Cell Line; Digestive System; Hydrogen-Ion Concentration; Immunohistochemistry; Intestinal Absorption; Lactic Acid; Molecular Sequence Data; Monocarboxylic Acid Transporters; Rats; Tissue Distribution; Transfection | 1999 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Nicotinic acid deficiency induced by sodium valproate.
Topics: Child; Humans; Male; Niacin; Pellagra; Valproic Acid | 1984 |
Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids.
Topics: Animals; Biological Transport; Carboxylic Acids; Carrier Proteins; CHO Cells; Cricetinae; Female; Hydrogen-Ion Concentration; Ibuprofen; Intestinal Mucosa; Lactates; Mandelic Acids; Membrane Proteins; Monocarboxylic Acid Transporters; Niacin; Oocytes; Pravastatin; Propionates; Protons; Rabbits; Recombinant Proteins; RNA, Complementary; RNA, Messenger; Stereoisomerism; Transcription, Genetic; Transfection; Valproic Acid; Xenopus laevis | 1995 |
[Pellagra in anticonvulsive therapy].
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Ethosuximide; Female; Humans; Intellectual Disability; Pellagra; Phenytoin; Photosensitivity Disorders; Valproic Acid; Vitamins | 1990 |